Patents by Inventor Patricia McLoughlin

Patricia McLoughlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Predictive marker for EGFR inhibitor treatment
    Patent number: 9121067
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: September 1, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110312981
    Abstract: The present invention provides a biomarker SFRS7 which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: December 22, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110245279
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients
    Type: Application
    Filed: August 7, 2008
    Publication date: October 6, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110230506
    Abstract: The present invention provides a biomarker (RAPGEF5) that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: September 22, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKERS FOR EGFR INHIBITORS TREATMENT
    Publication number: 20110218212
    Abstract: The present invention provides biomarkers that are predictive for the response to treatment with an EGFR inhibitor in cancer patients. The markers are the genes GBAS, APOH, SCYL3, PMS2CL, PRODH, SERF1A, URG4A and LRRC31.
    Type: Application
    Filed: August 7, 2008
    Publication date: September 8, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verna Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110212979
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: September 1, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110195982
    Abstract: The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients
    Type: Application
    Filed: August 7, 2008
    Publication date: August 11, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110190321
    Abstract: The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: August 4, 2011
    Inventors: Paul Delmar, Barbara Kiughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110184005
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: July 28, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110184004
    Abstract: The present invention provides biomarkers which are predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: July 28, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin